WELCH DANIEL G 4

What Happened
Daniel G. Welch, a director of Structure Therapeutics Inc., was granted 39,453 derivative Ordinary Shares on June 17, 2026. The Form 4 reports an acquisition price of $0 for the grant (i.e., a awarded/derivative grant rather than an open-market purchase or sale). The award is subject to vesting and is not an immediate sale or cash receipt.

Key Details

• Transaction date: 2026-06-17; Form 4 filed 2026-06-18 (timely).
• Transaction type/code: Grant/Award (reporting code A), derivative security.
• Shares granted: 39,453 Ordinary Shares; reported acquisition price $0.
• Vesting: Vesting in equal monthly installments over the 12 months following June 17, 2026; will be fully vested on the day before the issuer’s 2027 annual meeting (Footnote F2).
• Exercise price: Footnote states the option exercise price per share equals the fair market value per Ordinary Share on the grant date based on ADS trading (Footnote F1).
• ADS conversion: Ordinary Shares may be represented by ADSs; each ADS = 3 Ordinary Shares, so the grant equals 13,151 ADSs (Footnote F3).
• Shares owned after transaction: Not specified in the provided filing.

Context
This is a director compensation award (derivative/option-style) rather than an open-market buy or sale. Because the exercise price is set at fair market value on the grant date, the award only gains value if the share price rises above that exercise price. Director grants are common compensation and align long-term incentives but do not, by themselves, indicate insider buying or selling sentiment.